Theriva Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Selling, General & Admin	6.7	7.78	7.57	6.47	5.03	Upgrade
Research & Development	12.03	14.31	11.72	7.8	5.13	Upgrade
Operating Expenses	18.73	22.09	19.29	14.27	10.16	Upgrade
Operating Income	-18.73	-22.09	-19.29	-14.27	-10.16	Upgrade
Interest & Investment Income	0.7	1.44	0.51	0.01	0.04	Upgrade
Currency Exchange Gain (Loss)	-0	0	-0.04	-	-	Upgrade
EBT Excluding Unusual Items	-18.04	-20.65	-18.82	-14.27	-10.12	Upgrade
Merger & Restructuring Charges	-	-	-0.2	-	-	Upgrade
Impairment of Goodwill	-5.59	-	-	-	-	Upgrade
Other Unusual Items	-0.7	0.66	-2.09	-	-	Upgrade
Pretax Income	-25.65	-19.99	-21.11	-14.27	-10.12	Upgrade
Income Tax Expense	-	-1.64	-1.43	-	-	Upgrade
Earnings From Continuing Operations	-25.65	-18.35	-19.69	-14.27	-10.12	Upgrade
Minority Interest in Earnings	-	-	-	0	0.07	Upgrade
Net Income	-25.65	-18.35	-19.69	-14.27	-10.04	Upgrade
Preferred Dividends & Other Adjustments	-	-	0.34	8.92	2.51	Upgrade
Net Income to Common	-25.65	-18.35	-20.03	-23.19	-12.56	Upgrade
Shares Outstanding (Basic)	1	1	1	0	0	Upgrade
Shares Outstanding (Diluted)	1	1	1	0	0	Upgrade
Shares Change (YoY)	109.24%	5.09%	25.76%	541.07%	15.65%	Upgrade
EPS (Basic)	-19.03	-28.48	-32.66	-47.57	-165.13	Upgrade
EPS (Diluted)	-19.03	-28.48	-32.66	-47.57	-165.13	Upgrade
Free Cash Flow	-16.94	-19.2	-19.2	-12.9	-12.18	Upgrade
Free Cash Flow Per Share	-12.56	-29.80	-31.31	-26.47	-160.13	Upgrade
EBITDA	-18.59	-21.96	-19.21	-14.19	-9.96	Upgrade
D&A For EBITDA	0.14	0.14	0.09	0.09	0.2	Upgrade
EBIT	-18.73	-22.09	-19.29	-14.27	-10.16	Upgrade

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q